{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T16:00:38Z","timestamp":1784563238362,"version":"3.55.0"},"reference-count":108,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,10]]},"DOI":"10.7759\/cureus.98926","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T01:42:37Z","timestamp":1765417357000},"source":"Crossref","is-referenced-by-count":1,"title":["Nanovesicular Drug Delivery Systems for Overcoming Antibiotic Resistance"],"prefix":"10.7759","author":[{"given":"Gopalakrishna","family":"Pillai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish","family":"Jankie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S234610","article-title":"Antimicrobial resistance: implications and costs","volume":"12","author":"Dadgostar P","year":"2019","unstructured":"Dadgostar P. Antimicrobial resistance: implications and costs. Infect Drug Resist. 2019, 12:3903-10. 10.2147\/IDR.S234610","journal-title":"Infect Drug Resist"},{"key":"ref2","unstructured":"Global Antimicrobial Resistance and Use Surveillance System (GLASS) report. (2014). Accessed. October 2, 2025: https:\/\/www.who.int\/publications\/i\/item\/9789241564748."},{"key":"ref3","unstructured":"Global Antimicrobial Resistance and Use Surveillance System (GLASS) report 2022. (2022). Accessed. October 2, 2025: https:\/\/iris.who.int\/bitstream\/handle\/10665\/364996\/9789240062702-eng.pdf."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.VMBF-0016-2015","article-title":"Mechanisms of antibiotic resistance","volume":"4","author":"Munita JM","year":"2016","unstructured":"Munita JM, Arias CA. Mechanisms of antibiotic resistance. Microbiol Spectr. 2016, 4:10.1128\/microbiolspec.VMBF-0016-2015","journal-title":"Microbiol Spectr"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S401663","article-title":"Quinolone antibiotics: resistance and therapy","volume":"16","author":"Tang K","year":"2023","unstructured":"Tang K, Zhao H. Quinolone antibiotics: resistance and therapy. Infect Drug Resist. 2023, 16:811-20. 10.2147\/IDR.S401663","journal-title":"Infect Drug Resist"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.000475","article-title":"Mechanisms of quinolone action and resistance: where do we stand?","volume":"66","author":"Correia S","year":"2017","unstructured":"Correia S, Poeta P, H\u00e9braud M, Capelo JL, Igrejas G. Mechanisms of quinolone action and resistance: where do we stand?. J Med Microbiol. 2017, 66:551-9. 10.1099\/jmm.0.000475","journal-title":"J Med Microbiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.77.7.3974","article-title":"Active efflux of tetracycline encoded by four genetically different tetracycline resistance determinants in Escherichia coli","volume":"77","author":"McMurry L","year":"1980","unstructured":"McMurry L, Petrucci RE Jr, Levy SB. Active efflux of tetracycline encoded by four genetically different tetracycline resistance determinants in Escherichia coli. Proc Natl Acad Sci U S A. 1980, 77:3974-7. 10.1073\/pnas.77.7.3974","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki171","article-title":"Efflux-mediated antimicrobial resistance","volume":"56","author":"Poole K","year":"2005","unstructured":"Poole K. Efflux-mediated antimicrobial resistance. J Antimicrob Chemother. 2005, 56:20-51. 10.1093\/jac\/dki171","journal-title":"J Antimicrob Chemother"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.4.1145-1150.2004","article-title":"Expression of acrB, acrF, acrD, marA, and soxS in Salmonella enterica serovar Typhimurium: role in multiple antibiotic resistance","volume":"48","author":"Eaves DJ","year":"2004","unstructured":"Eaves DJ, Ricci V, Piddock LJ. Expression of acrB, acrF, acrD, marA, and soxS in Salmonella enterica serovar Typhimurium: role in multiple antibiotic resistance. Antimicrob Agents Chemother. 2004, 48:1145-50. 10.1128\/AAC.48.4.1145-1150.2004","journal-title":"Antimicrob Agents Chemother"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1128\/JB.183.20.5803-5812.2001","article-title":"Analysis of a complete library of putative drug transporter genes in Escherichia coli","volume":"183","author":"Nishino K","year":"2001","unstructured":"Nishino K, Yamaguchi A. Analysis of a complete library of putative drug transporter genes in Escherichia coli. J Bacteriol. 2001, 183:5803-12. 10.1128\/JB.183.20.5803-5812.2001","journal-title":"J Bacteriol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21145090","article-title":"Molecular mechanisms, epidemiology, and clinical importance of \u03b2-lactam resistance in Enterobacteriaceae","volume":"21","author":"De Angelis G","year":"2020","unstructured":"De Angelis G, Del Giacomo P, Posteraro B, Sanguinetti M, Tumbarello M. Molecular mechanisms, epidemiology, and clinical importance of \u03b2-lactam resistance in Enterobacteriaceae. Int J Mol Sci. 2020, 21:5090. 10.3390\/ijms21145090","journal-title":"Int J Mol Sci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.10.2262","article-title":"Modulation of biofilms of Pseudomonas aeruginosa by quinolones","volume":"39","author":"Yassien M","year":"1995","unstructured":"Yassien M, Khardori N, Ahmedy A, Toama M. Modulation of biofilms of Pseudomonas aeruginosa by quinolones. Antimicrob Agents Chemother. 1995, 39:2262-8. 10.1128\/AAC.39.10.2262","journal-title":"Antimicrob Agents Chemother"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10010003","article-title":"Biofilms as promoters of bacterial antibiotic resistance and tolerance","volume":"10","author":"Uru\u00e9n C","year":"2020","unstructured":"Uru\u00e9n C, Chopo-Escuin G, Tommassen J, Mainar-Jaime RC, Arenas J. Biofilms as promoters of bacterial antibiotic resistance and tolerance. Antibiotics (Basel). 2020, 10:3. 10.3390\/antibiotics10010003","journal-title":"Antibiotics (Basel)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-015-2323-z","article-title":"Biofilm-specific antibiotic tolerance and resistance","volume":"34","author":"Olsen I","year":"2015","unstructured":"Olsen I. Biofilm-specific antibiotic tolerance and resistance. Eur J Clin Microbiol Infect Dis. 2015, 34:877-86. 10.1007\/s10096-015-2323-z","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/0924-8579(94)90018-3","article-title":"Comparative evaluation of fleroxacin, ampicillin, trimethoprimsulfamethoxazole, and gentamicin as treatments of catheter-associated urinary tract infection in a rabbit model","volume":"4 Suppl 2","author":"Morck DW","year":"1994","unstructured":"Morck DW, Lam K, McKay SG, et al.. Comparative evaluation of fleroxacin, ampicillin, trimethoprimsulfamethoxazole, and gentamicin as treatments of catheter-associated urinary tract infection in a rabbit model. Int J Antimicrob Agents. 1994, 4 Suppl 2:S21-7. 10.1016\/0924-8579(94)90018-3","journal-title":"Int J Antimicrob Agents"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.37.6.1771-1776.1999","article-title":"The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms","volume":"37","author":"Ceri H","year":"1999","unstructured":"Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol. 1999, 37:1771-6. 10.1128\/JCM.37.6.1771-1776.1999","journal-title":"J Clin Microbiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1177\/00185787251341739","article-title":"Vancomycin-induced DRESS syndrome: a systematic review of case reports","author":"Bhumireddy SK","year":"2025","unstructured":"Bhumireddy SK, Gudla SS, Vadaga AK, Nandula MS. Vancomycin-induced DRESS syndrome: a systematic review of case reports. Hosp Pharm. 2025, 00185787251341739. 10.1177\/00185787251341739","journal-title":"Hosp Pharm"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15061593","article-title":"Solid lipid nanoparticles vs. nanostructured lipid carriers: a comparative review","volume":"15","author":"Viegas C","year":"2023","unstructured":"Viegas C, Patr\u00edcio AB, Prata JM, Nadhman A, Chintamaneni PK, Fonte P. Solid lipid nanoparticles vs. nanostructured lipid carriers: a comparative review. Pharmaceutics. 2023, 15:1593. 10.3390\/pharmaceutics15061593","journal-title":"Pharmaceutics"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s11671-023-03943-0","article-title":"Exploration of inorganic nanoparticles for revolutionary drug delivery applications: a critical\u00a0review","volume":"18","author":"Unnikrishnan G","year":"2023","unstructured":"Unnikrishnan G, Joy A, Megha M, Kolanthai E, Senthilkumar M. Exploration of inorganic nanoparticles for revolutionary drug delivery applications: a critical\u00a0review. Discov Nano. 2023, 18:157. 10.1186\/s11671-023-03943-0","journal-title":"Discov Nano"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.3c01117","article-title":"Microfluidic devices: a tool for nanoparticle synthesis and performance evaluation","volume":"17","author":"Gimondi S","year":"2023","unstructured":"Gimondi S, Ferreira H, Reis RL, Neves NM. Microfluidic devices: a tool for nanoparticle synthesis and performance evaluation. ACS Nano. 2023, 17:14205-28. 10.1021\/acsnano.3c01117","journal-title":"ACS Nano"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11020200","article-title":"Progress in alternative strategies to combat antimicrobial resistance: focus on antibiotics","volume":"11","author":"Murugaiyan J","year":"2022","unstructured":"Murugaiyan J, Kumar PA, Rao GS, et al.. Progress in alternative strategies to combat antimicrobial resistance: focus on antibiotics. Antibiotics (Basel). 2022, 11:200. 10.3390\/antibiotics11020200","journal-title":"Antibiotics (Basel)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11020413","article-title":"Nanotechnology as a promising approach to combat multidrug resistant bacteria: a comprehensive review and future perspectives","volume":"11","author":"Hetta HF","year":"2023","unstructured":"Hetta HF, Ramadan YN, Al-Harbi AI, et al.. Nanotechnology as a promising approach to combat multidrug resistant bacteria: a comprehensive review and future perspectives. Biomedicines. 2023, 11:413. 10.3390\/biomedicines11020413","journal-title":"Biomedicines"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199700544-00004","article-title":"Liposomes. Opportunities in drug delivery","volume":"54 Suppl 4","author":"Allen TM","year":"1997","unstructured":"Allen TM. Liposomes. Opportunities in drug delivery. Drugs. 1997, 54 Suppl 4:8-14. 10.2165\/00003495-199700544-00004","journal-title":"Drugs"},{"key":"ref24","article-title":"Niosomes as drug carriers","volume":"31","author":"Malhotra M","year":"1994","unstructured":"Malhotra M, Jain NK. Niosomes as drug carriers. Indian Drugs. 1994, 31:81-6.","journal-title":"Indian Drugs"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13071070","article-title":"Rifampicin-liposomes for Mycobacterium abscessus infection treatment: intracellular uptake and antibacterial activity evaluation","volume":"13","author":"Rinaldi F","year":"2021","unstructured":"Rinaldi F, Hanieh PN, Sennato S, et al.. Rifampicin-liposomes for Mycobacterium abscessus infection treatment: intracellular uptake and antibacterial activity evaluation. Pharmaceutics. 2021, 13:1070. 10.3390\/pharmaceutics13071070","journal-title":"Pharmaceutics"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2007.08.008","article-title":"Rifabutin encapsulated in liposomes exhibits increased therapeutic activity in a model of disseminated tuberculosis","volume":"31","author":"Gaspar MM","year":"2008","unstructured":"Gaspar MM, Cruz A, Penha AF, et al.. Rifabutin encapsulated in liposomes exhibits increased therapeutic activity in a model of disseminated tuberculosis. Int J Antimicrob Agents. 2008, 31:37-45. 10.1016\/j.ijantimicag.2007.08.008","journal-title":"Int J Antimicrob Agents"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/ph17040470","article-title":"Liposomal rifabutin-A promising antibiotic repurposing strategy against methicillin-resistant Staphylococcus aureus infections","volume":"17","author":"Pinho JO","year":"2024","unstructured":"Pinho JO, Ferreira M, Coelho M, Pinto SN, Aguiar SI, Gaspar MM. Liposomal rifabutin-A promising antibiotic repurposing strategy against methicillin-resistant Staphylococcus aureus infections. Pharmaceuticals (Basel). 2024, 17:470. 10.3390\/ph17040470","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26072047","article-title":"Liposomes as antibiotic delivery systems: a promising nanotechnological strategy against antimicrobial resistance","volume":"26","author":"Ferreira M","year":"2021","unstructured":"Ferreira M, Ogren M, Dias JN, et al.. Liposomes as antibiotic delivery systems: a promising nanotechnological strategy against antimicrobial resistance. Molecules. 2021, 26:2047. 10.3390\/molecules26072047","journal-title":"Molecules"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S186571","article-title":"Synergistic antibacterial effect of ultrasound microbubbles combined with chitosan-modified polymyxin B-loaded liposomes on biofilm-producing Acinetobacter baumannii","volume":"14","author":"Fu YY","year":"2019","unstructured":"Fu YY, Zhang L, Yang Y, Liu CW, He YN, Li P, Yu X. Synergistic antibacterial effect of ultrasound microbubbles combined with chitosan-modified polymyxin B-loaded liposomes on biofilm-producing Acinetobacter baumannii. Int J Nanomedicine. 2019, 14:1805-15. 10.2147\/IJN.S186571","journal-title":"Int J Nanomedicine"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2015.01.016","article-title":"Nanotechnology approaches for antibacterial drug delivery: preparation and microbiological evaluation of fusogenic liposomes carrying fusidic acid","volume":"45","author":"Nicolosi D","year":"2015","unstructured":"Nicolosi D, Cupri S, Genovese C, Tempera G, Mattina R, Pignatello R. Nanotechnology approaches for antibacterial drug delivery: preparation and microbiological evaluation of fusogenic liposomes carrying fusidic acid. Int J Antimicrob Agents. 2015, 45:622-6. 10.1016\/j.ijantimicag.2015.01.016","journal-title":"Int J Antimicrob Agents"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2010.01.015","article-title":"Encapsulation in fusogenic liposomes broadens the spectrum of action of vancomycin against Gram-negative bacteria","volume":"35","author":"Nicolosi D","year":"2010","unstructured":"Nicolosi D, Scalia M, Nicolosi VM, Pignatello R. Encapsulation in fusogenic liposomes broadens the spectrum of action of vancomycin against Gram-negative bacteria. Int J Antimicrob Agents. 2010, 35:553-8. 10.1016\/j.ijantimicag.2010.01.015","journal-title":"Int J Antimicrob Agents"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01547-05","article-title":"Mechanism of enhanced activity of liposome-entrapped aminoglycosides against resistant strains of Pseudomonas aeruginosa","volume":"50","author":"Mugabe C","year":"2006","unstructured":"Mugabe C, Halwani M, Azghani AO, Lafrenie RM, Omri A. Mechanism of enhanced activity of liposome-entrapped aminoglycosides against resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2006, 50:2016-22. 10.1128\/AAC.01547-05","journal-title":"Antimicrob Agents Chemother"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2005.10.021","article-title":"Antibacterial activity of liposomal gentamicin against Pseudomonas aeruginosa: a time-kill study","volume":"27","author":"Rukholm G","year":"2006","unstructured":"Rukholm G, Mugabe C, Azghani AO, Omri A. Antibacterial activity of liposomal gentamicin against Pseudomonas aeruginosa: a time-kill study. Int J Antimicrob Agents. 2006, 27:247-52. 10.1016\/j.ijantimicag.2005.10.021","journal-title":"Int J Antimicrob Agents"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12080769","article-title":"Hybrid pectin-liposome formulation against multi-resistant bacterial strains","volume":"12","author":"Ribeiro LN","year":"2020","unstructured":"Ribeiro LN, de Paula E, Rossi DA, et al.. Hybrid pectin-liposome formulation against multi-resistant bacterial strains. Pharmaceutics. 2020, 12:769. 10.3390\/pharmaceutics12080769","journal-title":"Pharmaceutics"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.9.2458-2464.2000","article-title":"Ofloxacin-loaded liposomes: in vitro activity and drug accumulation in bacteria","volume":"44","author":"Furneri PM","year":"2000","unstructured":"Furneri PM, Fresta M, Puglisi G, Tempera G. Ofloxacin-loaded liposomes: in vitro activity and drug accumulation in bacteria. Antimicrob Agents Chemother. 2000, 44:2458-64. 10.1128\/AAC.44.9.2458-2464.2000","journal-title":"Antimicrob Agents Chemother"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11020069","article-title":"Preparation and characterization of new liposomes. Bactericidal activity of cefepime encapsulated into cationic liposomes","volume":"11","author":"Moy\u00e1 ML","year":"2019","unstructured":"Moy\u00e1 ML, L\u00f3pez-L\u00f3pez M, Lebr\u00f3n JA, et al.. Preparation and characterization of new liposomes. Bactericidal activity of cefepime encapsulated into cationic liposomes. Pharmaceutics. 2019, 11:69. 10.3390\/pharmaceutics11020069","journal-title":"Pharmaceutics"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S211691","article-title":"Azithromycin-liposomes as a novel approach for localized therapy of cervicovaginal bacterial infections","volume":"14","author":"Vani\u0107 \u017d","year":"2019","unstructured":"Vani\u0107 \u017d, Rukavina Z, Manner S, et al.. Azithromycin-liposomes as a novel approach for localized therapy of cervicovaginal bacterial infections. Int J Nanomedicine. 2019, 14:5957-76. 10.2147\/IJN.S211691","journal-title":"Int J Nanomedicine"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.1.45","article-title":"Antibacterial efficacy against an in vivo Salmonella typhimurium infection model and pharmacokinetics of a liposomal ciprofloxacin formulation","volume":"42","author":"Webb MS","year":"1998","unstructured":"Webb MS, Boman NL, Wiseman DJ, et al.. Antibacterial efficacy against an in vivo Salmonella typhimurium infection model and pharmacokinetics of a liposomal ciprofloxacin formulation. Antimicrob Agents Chemother. 1998, 42:45-52. 10.1128\/AAC.42.1.45","journal-title":"Antimicrob Agents Chemother"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.27.1.137","article-title":"Enhanced liposome-mediated activity of piperacillin against staphylococci","volume":"27","author":"Nacucchio MC","year":"1985","unstructured":"Nacucchio MC, Bellora MJ, Sordelli DO, D'Aquino M. Enhanced liposome-mediated activity of piperacillin against staphylococci. Antimicrob Agents Chemother. 1985, 27:137-9. 10.1128\/AAC.27.1.137","journal-title":"Antimicrob Agents Chemother"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks212","article-title":"Liposomal encapsulation of vancomycin improves killing of methicillin-resistant Staphylococcus aureus in a murine infection model","volume":"67","author":"Sande L","year":"2012","unstructured":"Sande L, Sanchez M, Montes J, Wolf AJ, Morgan MA, Omri A, Liu GY. Liposomal encapsulation of vancomycin improves killing of methicillin-resistant Staphylococcus aureus in a murine infection model. J Antimicrob Chemother. 2012, 67:2191-4. 10.1093\/jac\/dks212","journal-title":"J Antimicrob Chemother"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.121356","article-title":"Bacteria-targeting liposomes for enhanced delivery of cinnamaldehyde and infection management","volume":"612","author":"Sang N","year":"2022","unstructured":"Sang N, Jiang L, Wang Z, Zhu Y, Lin G, Li R, Zhang J. Bacteria-targeting liposomes for enhanced delivery of cinnamaldehyde and infection management. Int J Pharm. 2022, 612:121356. 10.1016\/j.ijpharm.2021.121356","journal-title":"Int J Pharm"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1111\/cmi.12485","article-title":"Inability to sustain intraphagolysosomal killing of Staphylococcus aureus predisposes to bacterial persistence in macrophages","volume":"18","author":"Jubrail J","year":"2016","unstructured":"Jubrail J, Morris P, Bewley MA, et al.. Inability to sustain intraphagolysosomal killing of Staphylococcus aureus predisposes to bacterial persistence in macrophages. Cell Microbiol. 2016, 18:80-96. 10.1111\/cmi.12485","journal-title":"Cell Microbiol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/s0891-5520(03)00066-7","article-title":"Intracellular pharmacodynamics of antibiotics","volume":"17","author":"Carryn S","year":"2003","unstructured":"Carryn S, Chanteux H, Seral C, Mingeot-Leclercq MP, Van Bambeke F, Tulkens PM. Intracellular pharmacodynamics of antibiotics. Infect Dis Clin North Am. 2003, 17:615-34. 10.1016\/s0891-5520(03)00066-7","journal-title":"Infect Dis Clin North Am"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1007\/BF01964420","article-title":"Intracellular distribution and activity of antibiotics","volume":"10","author":"Tulkens PM","year":"1991","unstructured":"Tulkens PM. Intracellular distribution and activity of antibiotics. Eur J Clin Microbiol Infect Dis. 1991, 10:100-6. 10.1007\/BF01964420","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.02.009","article-title":"Nanocarriers for antibiotics: a promising solution to treat intracellular bacterial infections","volume":"43","author":"Abed N","year":"2014","unstructured":"Abed N, Couvreur P. Nanocarriers for antibiotics: a promising solution to treat intracellular bacterial infections. Int J Antimicrob Agents. 2014, 43:485-96. 10.1016\/j.ijantimicag.2014.02.009","journal-title":"Int J Antimicrob Agents"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(78)90370-2","article-title":"The uptake and intracellular accumulation of aminoglycoside antibiotics in lysosomes of cultured rat fibroblasts","volume":"27","author":"Tulkens P","year":"1978","unstructured":"Tulkens P, Trouet A. The uptake and intracellular accumulation of aminoglycoside antibiotics in lysosomes of cultured rat fibroblasts. Biochem Pharmacol. 1978, 27:415-24. 10.1016\/0006-2952(78)90370-2","journal-title":"Biochem Pharmacol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1007\/BF02771843","article-title":"Intracellular activity of vancomycin and Ly333328, a new semisynthetic glycopeptide, against methicillin-resistant Staphylococcus aureus","volume":"26","author":"al-Nawas B","year":"1998","unstructured":"al-Nawas B, Shah PM. Intracellular activity of vancomycin and Ly333328, a new semisynthetic glycopeptide, against methicillin-resistant Staphylococcus aureus. Infection. 1998, 26:165-7. 10.1007\/BF02771843","journal-title":"Infection"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.3390\/ph3041139","article-title":"Lysostaphin: a staphylococcal bacteriolysin with potential clinical applications","volume":"3","author":"Bastos MD","year":"2010","unstructured":"Bastos MD, Coutinho BG, Coelho ML. Lysostaphin: a staphylococcal bacteriolysin with potential clinical applications. Pharmaceuticals (Basel). 2010, 3:1139-61. 10.3390\/ph3041139","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.11.3407-3414.2003","article-title":"Lysostaphin disrupts Staphylococcus aureus and Staphylococcus epidermidis biofilms on artificial surfaces","volume":"47","author":"Wu JA","year":"2003","unstructured":"Wu JA, Kusuma C, Mond JJ, Kokai-Kun JF. Lysostaphin disrupts Staphylococcus aureus and Staphylococcus epidermidis biofilms on artificial surfaces. Antimicrob Agents Chemother. 2003, 47:3407-14. 10.1128\/AAC.47.11.3407-3414.2003","journal-title":"Antimicrob Agents Chemother"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1128\/JB.188.7.2463-2472.2006","article-title":"Cross-linked peptidoglycan mediates lysostaphin binding to the cell wall envelope of Staphylococcus aureus","volume":"188","author":"Gr\u00fcndling A","year":"2006","unstructured":"Gr\u00fcndling A, Schneewind O. Cross-linked peptidoglycan mediates lysostaphin binding to the cell wall envelope of Staphylococcus aureus. J Bacteriol. 2006, 188:2463-72. 10.1128\/JB.188.7.2463-2472.2006","journal-title":"J Bacteriol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S214521","article-title":"The bactericidal effect of lysostaphin coupled with liposomal vancomycin as a dual combating system applied directly on methicillin-resistant Staphylococcus aureus infected skin wounds in mice","volume":"14","author":"Hajiahmadi F","year":"2019","unstructured":"Hajiahmadi F, Alikhani MY, Shariatifar H, Arabestani MR, Ahmadvand D. The bactericidal effect of lysostaphin coupled with liposomal vancomycin as a dual combating system applied directly on methicillin-resistant Staphylococcus aureus infected skin wounds in mice. Int J Nanomedicine. 2019, 14:5943-55. 10.2147\/IJN.S214521","journal-title":"Int J Nanomedicine"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S51303","article-title":"Clinical experimentation with aerosol antibiotics: current and future methods of administration","volume":"7","author":"Zarogoulidis P","year":"2013","unstructured":"Zarogoulidis P, Kioumis I, Porpodis K, et al.. Clinical experimentation with aerosol antibiotics: current and future methods of administration. Drug Des Devel Ther. 2013, 7:1115-34. 10.2147\/DDDT.S51303","journal-title":"Drug Des Devel Ther"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2019.05.068","article-title":"Ciprofloxacin nanocrystals liposomal powders for controlled drug release via inhalation","volume":"566","author":"Khatib I","year":"2019","unstructured":"Khatib I, Khanal D, Ruan J, Cipolla D, Dayton F, Blanchard JD, Chan HK. Ciprofloxacin nanocrystals liposomal powders for controlled drug release via inhalation. Int J Pharm. 2019, 566:641-51. 10.1016\/j.ijpharm.2019.05.068","journal-title":"Int J Pharm"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01359-z","article-title":"Inhaled liposomal antimicrobial delivery in lung infections","volume":"80","author":"Bassetti M","year":"2020","unstructured":"Bassetti M, Vena A, Russo A, Peghin M. Inhaled liposomal antimicrobial delivery in lung infections. Drugs. 2020, 80:1309-18. 10.1007\/s40265-020-01359-z","journal-title":"Drugs"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.3109\/03639045.2013.858740","article-title":"In-vitro and in-vivo evaluation of ciprofloxacin liposomes for pulmonary administration","volume":"41","author":"Liu C","year":"2015","unstructured":"Liu C, Shi J, Dai Q, Yin X, Zhang X, Zheng A. In-vitro and in-vivo evaluation of ciprofloxacin liposomes for pulmonary administration. Drug Dev Ind Pharm. 2015, 41:272-8. 10.3109\/03639045.2013.858740","journal-title":"Drug Dev Ind Pharm"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2012.48.5.1789474","article-title":"Inhaled antibiotics for lower respiratory tract infections: focus on ciprofloxacin","volume":"48","author":"Serisier DJ","year":"2012","unstructured":"Serisier DJ. Inhaled antibiotics for lower respiratory tract infections: focus on ciprofloxacin. Drugs Today (Barc). 2012, 48:339-51. 10.1358\/dot.2012.48.5.1789474","journal-title":"Drugs Today (Barc)"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-018-2464-8","article-title":"Co-delivery of ciprofloxacin and colistin in liposomal formulations with enhanced in vitro antimicrobial activities against multidrug resistant Pseudomonas aeruginosa","volume":"35","author":"Wang S","year":"2018","unstructured":"Wang S, Yu S, Lin Y, et al.. Co-delivery of ciprofloxacin and colistin in liposomal formulations with enhanced in vitro antimicrobial activities against multidrug resistant Pseudomonas aeruginosa. Pharm Res. 2018, 35:187. 10.1007\/s11095-018-2464-8","journal-title":"Pharm Res"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2024.107661","article-title":"Inhaled antibiotics: a promising drug delivery strategies for efficient treatment of lower respiratory tract infections (LRTIs) associated with antibiotic resistant biofilm-dwelling and intracellular bacterial pathogens","volume":"227","author":"Islam N","year":"2024","unstructured":"Islam N, Reid D. Inhaled antibiotics: a promising drug delivery strategies for efficient treatment of lower respiratory tract infections (LRTIs) associated with antibiotic resistant biofilm-dwelling and intracellular bacterial pathogens. Respir Med. 2024, 227:107661. 10.1016\/j.rmed.2024.107661","journal-title":"Respir Med"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1086\/644732","article-title":"Topical antimicrobial therapy for treating chronic wounds","volume":"49","author":"Lipsky BA","year":"2009","unstructured":"Lipsky BA, Hoey C. Topical antimicrobial therapy for treating chronic wounds. Clin Infect Dis. 2009, 49:1541-9. 10.1086\/644732","journal-title":"Clin Infect Dis"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-019-0514-y","article-title":"Nano-drug delivery systems in wound treatment and skin regeneration","volume":"17","author":"Wang W","year":"2019","unstructured":"Wang W, Lu KJ, Yu CH, Huang QL, Du YZ. Nano-drug delivery systems in wound treatment and skin regeneration. J Nanobiotechnology. 2019, 17:82. 10.1186\/s12951-019-0514-y","journal-title":"J Nanobiotechnology"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/0022-4804(90)90258-4","article-title":"Topical liposomal delivery of antibiotics in soft tissue infection","volume":"49","author":"Price CI","year":"1990","unstructured":"Price CI, Horton JW, Baxter CR. Topical liposomal delivery of antibiotics in soft tissue infection. J Surg Res. 1990, 49:174-8. 10.1016\/0022-4804(90)90258-4","journal-title":"J Surg Res"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S141887","article-title":"Efficacy and tolerability of liposomal polyvinylpyrrolidone-iodine hydrogel for the localized treatment of chronic infective, inflammatory, dermatoses: an uncontrolled pilot study","volume":"10","author":"Augustin M","year":"2017","unstructured":"Augustin M, Goepel L, Jacobi A, Bosse B, Mueller S, Hopp M. Efficacy and tolerability of liposomal polyvinylpyrrolidone-iodine hydrogel for the localized treatment of chronic infective, inflammatory, dermatoses: an uncontrolled pilot study. Clin Cosmet Investig Dermatol. 2017, 10:373-84. 10.2147\/CCID.S141887","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-020-00791-8","article-title":"Lipid-based nanosystems for targeting bone implant-associated infections: current approaches and future endeavors","volume":"11","author":"Ferreira M","year":"2021","unstructured":"Ferreira M, Aguiar S, Bettencourt A, Gaspar MM. Lipid-based nanosystems for targeting bone implant-associated infections: current approaches and future endeavors. Drug Deliv Transl Res. 2021, 11:72-85. 10.1007\/s13346-020-00791-8","journal-title":"Drug Deliv Transl Res"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2008.09.043","article-title":"The interaction between Pseudomonas aeruginosa cells and cationic PC:Chol:DOTAP liposomal vesicles versus outer-membrane structure and envelope properties of bacterial cell","volume":"367","author":"Drulis-Kawa Z","year":"2009","unstructured":"Drulis-Kawa Z, Dorotkiewicz-Jach A, Gubernator J, Gula G, Bocer T, Doroszkiewicz W. The interaction between Pseudomonas aeruginosa cells and cationic PC:Chol:DOTAP liposomal vesicles versus outer-membrane structure and envelope properties of bacterial cell. Int J Pharm. 2009, 367:211-9. 10.1016\/j.ijpharm.2008.09.043","journal-title":"Int J Pharm"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1007\/s12274-020-2655-6","article-title":"The enhanced permeability and retention effect based nanomedicine at the site of injury","volume":"13","author":"Liu Y","year":"2020","unstructured":"Liu Y, Sun D, Fan Q, et al.. The enhanced permeability and retention effect based nanomedicine at the site of injury. Nano Res. 2020, 13:564-9. 10.1007\/s12274-020-2655-6","journal-title":"Nano Res"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00155","article-title":"The multirole of liposomes in therapy and prevention of infectious diseases","volume":"9","author":"Nisini R","year":"2018","unstructured":"Nisini R, Poerio N, Mariotti S, De Santis F, Fraziano M. The multirole of liposomes in therapy and prevention of infectious diseases. Front Immunol. 2018, 9:155. 10.3389\/fimmu.2018.00155","journal-title":"Front Immunol"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S49297","article-title":"Thermosensitive liposomal drug delivery systems: state of the art review","volume":"9","author":"Kneidl B","year":"2014","unstructured":"Kneidl B, Peller M, Winter G, Lindner LH, Hossann M. Thermosensitive liposomal drug delivery systems: state of the art review. Int J Nanomedicine. 2014, 9:4387-98. 10.2147\/IJN.S49297","journal-title":"Int J Nanomedicine"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.2013.822860","article-title":"Liposomal antibiotics for the treatment of infectious diseases","volume":"10","author":"Alhariri M","year":"2013","unstructured":"Alhariri M, Azghani A, Omri A. Liposomal antibiotics for the treatment of infectious diseases. Expert Opin Drug Deliv. 2013, 10:1515-32. 10.1517\/17425247.2013.822860","journal-title":"Expert Opin Drug Deliv"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2020.11.045","article-title":"Eradicating intracellular MRSA via targeted delivery of lysostaphin and vancomycin with mannose-modified exosomes","volume":"329","author":"Yang X","year":"2021","unstructured":"Yang X, Xie B, Peng H, et al.. Eradicating intracellular MRSA via targeted delivery of lysostaphin and vancomycin with mannose-modified exosomes. J Control Release. 2021, 329:454-67. 10.1016\/j.jconrel.2020.11.045","journal-title":"J Control Release"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.2217\/nnm.15.134","article-title":"Nanoparticulate platforms for targeting bone infections: meeting a major therapeutic challenge","volume":"10","author":"Santos-Ferreira I","year":"2015","unstructured":"Santos-Ferreira I, Bettencourt A, Almeida AJ. Nanoparticulate platforms for targeting bone infections: meeting a major therapeutic challenge. Nanomedicine (Lond). 2015, 10:3131-45. 10.2217\/nnm.15.134","journal-title":"Nanomedicine (Lond)"},{"key":"ref71","article-title":"Antibiotic-loaded bone cement in total joint arthroplasty","volume":"81","author":"Soares D","year":"2015","unstructured":"Soares D, Leite P, Barreira P, Aido R, Sousa R. Antibiotic-loaded bone cement in total joint arthroplasty. Acta Orthop Belg. 2015, 81:184-90.","journal-title":"Acta Orthop Belg"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.E.01126","article-title":"Antibiotic-loaded bone cement for infection prophylaxis in total joint replacement","volume":"88","author":"Jiranek WA","year":"2006","unstructured":"Jiranek WA, Hanssen AD, Greenwald AS. Antibiotic-loaded bone cement for infection prophylaxis in total joint replacement. J Bone Joint Surg Am. 2006, 88:2487-500. 10.2106\/JBJS.E.01126","journal-title":"J Bone Joint Surg Am"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.5402\/2011\/290851","article-title":"Antibiotic-loaded cement in orthopedic surgery: a review","volume":"2011","author":"Bistolfi A","year":"2011","unstructured":"Bistolfi A, Massazza G, Vern\u00e9 E, et al.. Antibiotic-loaded cement in orthopedic surgery: a review. ISRN Orthop. 2011, 2011:290851. 10.5402\/2011\/290851","journal-title":"ISRN Orthop"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2017.08.089","article-title":"Levofloxacin-loaded bone cement delivery system: highly effective against intracellular bacteria and Staphylococcus aureus biofilms","volume":"532","author":"Ferreira M","year":"2017","unstructured":"Ferreira M, Rzhepishevska O, Grenho L, et al.. Levofloxacin-loaded bone cement delivery system: highly effective against intracellular bacteria and Staphylococcus aureus biofilms. Int J Pharm. 2017, 532:241-8. 10.1016\/j.ijpharm.2017.08.089","journal-title":"Int J Pharm"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1016\/j.msec.2016.04.062","article-title":"The use of nanomaterials to treat bone infections","volume":"67","author":"Snoddy B","year":"2016","unstructured":"Snoddy B, Jayasuriya AC. The use of nanomaterials to treat bone infections. Mater Sci Eng C Mater Biol Appl. 2016, 67:822-33. 10.1016\/j.msec.2016.04.062","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1007\/s00402-008-0782-8","article-title":"Treatment of osteomyelitis by liposomal gentamicin-impregnated calcium sulfate","volume":"129","author":"Hui T","year":"2009","unstructured":"Hui T, Yongqing X, Tiane Z, et al.. Treatment of osteomyelitis by liposomal gentamicin-impregnated calcium sulfate. Arch Orthop Trauma Surg. 2009, 129:1301-8. 10.1007\/s00402-008-0782-8","journal-title":"Arch Orthop Trauma Surg"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00007-10","article-title":"Penetration of drugs through the blood-cerebrospinal fluid\/blood-brain barrier for treatment of central nervous system infections","volume":"23","author":"Nau R","year":"2010","unstructured":"Nau R, S\u00f6rgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid\/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev. 2010, 23:858-83. 10.1128\/CMR.00007-10","journal-title":"Clin Microbiol Rev"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2015.06.067","article-title":"Dual ligand immunoliposomes for drug delivery to the brain","volume":"134","author":"Loureiro JA","year":"2015","unstructured":"Loureiro JA, Gomes B, Fricker G, et al.. Dual ligand immunoliposomes for drug delivery to the brain. Colloids Surf B Biointerfaces. 2015, 134:213-9. 10.1016\/j.colsurfb.2015.06.067","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1080\/1061186X.2016.1184272","article-title":"Nano carriers for drug transport across the blood-brain barrier","volume":"25","author":"Li X","year":"2017","unstructured":"Li X, Tsibouklis J, Weng T, et al.. Nano carriers for drug transport across the blood-brain barrier. J Drug Target. 2017, 25:17-28. 10.1080\/1061186X.2016.1184272","journal-title":"J Drug Target"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0194179","article-title":"Niosomes, an alternative for liposomal delivery","volume":"13","author":"Bartelds R","year":"2018","unstructured":"Bartelds R, Nematollahi MH, Pols T, Stuart MC, Pardakhty A, Asadikaram G, Poolman B. Niosomes, an alternative for liposomal delivery. PLoS One. 2018, 13:e0194179. 10.1371\/journal.pone.0194179","journal-title":"PLoS One"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26195905","article-title":"Controlled drug delivery systems: current status and future directions","volume":"26","author":"Adepu S","year":"2021","unstructured":"Adepu S, Ramakrishna S. Controlled drug delivery systems: current status and future directions. Molecules. 2021, 26:5905. 10.3390\/molecules26195905","journal-title":"Molecules"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12090837","article-title":"Recent advances in nanocarrier-assisted therapeutics delivery systems","volume":"12","author":"Su S","year":"2020","unstructured":"Su S, M Kang P. Recent advances in nanocarrier-assisted therapeutics delivery systems. Pharmaceutics. 2020, 12:837. 10.3390\/pharmaceutics12090837","journal-title":"Pharmaceutics"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.3390\/nano10061191","article-title":"Niosomal drug delivery systems for ocular disease-recent advances and future prospects","volume":"10","author":"Durak S","year":"2020","unstructured":"Durak S, Esmaeili Rad M, Alp Yetisgin A, Eda Sutova H, Kutlu O, Cetinel S, Zarrabi A. Niosomal drug delivery systems for ocular disease-recent advances and future prospects. Nanomaterials (Basel). 2020, 10:1191. 10.3390\/nano10061191","journal-title":"Nanomaterials (Basel)"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/263604","article-title":"Nonionic surfactant vesicles in ocular delivery: innovative approaches and perspectives","volume":"2014","author":"Sahoo RK","year":"2014","unstructured":"Sahoo RK, Biswas N, Guha A, Sahoo N, Kuotsu K. Nonionic surfactant vesicles in ocular delivery: innovative approaches and perspectives. Biomed Res Int. 2014, 2014:263604. 10.1155\/2014\/263604","journal-title":"Biomed Res Int"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-008-9105-1","article-title":"Niosome-encapsulated gentamicin for ophthalmic controlled delivery","volume":"9","author":"Abdelbary G","year":"2008","unstructured":"Abdelbary G, El-Gendy N. Niosome-encapsulated gentamicin for ophthalmic controlled delivery. AAPS PharmSciTech. 2008, 9:740-7. 10.1208\/s12249-008-9105-1","journal-title":"AAPS PharmSciTech"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2021.745099","article-title":"Streptomycin sulfate-loaded niosomes enables increased antimicrobial and anti-biofilm activities","volume":"9","author":"Mansouri M","year":"2021","unstructured":"Mansouri M, Khayam N, Jamshidifar E, et al.. Streptomycin sulfate-loaded niosomes enables increased antimicrobial and anti-biofilm activities. Front Bioeng Biotechnol. 2021, 9:745099. 10.3389\/fbioe.2021.745099","journal-title":"Front Bioeng Biotechnol"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1002\/jbm.a.37086","article-title":"Niosome-encapsulated tobramycin reduced antibiotic resistance and enhanced antibacterial activity against multidrug-resistant clinical strains of Pseudomonas aeruginosa","volume":"109","author":"Hedayati Ch M","year":"2021","unstructured":"Hedayati Ch M, Abolhassani Targhi A, Shamsi F, et al.. Niosome-encapsulated tobramycin reduced antibiotic resistance and enhanced antibacterial activity against multidrug-resistant clinical strains of Pseudomonas aeruginosa. J Biomed Mater Res A. 2021, 109:966-80. 10.1002\/jbm.a.37086","journal-title":"J Biomed Mater Res A"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1007\/s11274-022-03405-2","article-title":"Amikacin-loaded niosome nanoparticles improve amikacin activity against antibiotic-resistant Klebsiella pneumoniae strains","volume":"38","author":"Rahmati M","year":"2022","unstructured":"Rahmati M, Babapoor E, Dezfulian M. Amikacin-loaded niosome nanoparticles improve amikacin activity against antibiotic-resistant Klebsiella pneumoniae strains. World J Microbiol Biotechnol. 2022, 38:230. 10.1007\/s11274-022-03405-2","journal-title":"World J Microbiol Biotechnol"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1111\/jphp.13106","article-title":"Vancomycin-loaded niosomes integrated within pH-sensitive in-situ forming gel for treatment of ocular infections while minimizing drug irritation","volume":"71","author":"Allam A","year":"2019","unstructured":"Allam A, El-Mokhtar MA, Elsabahy M. Vancomycin-loaded niosomes integrated within pH-sensitive in-situ forming gel for treatment of ocular infections while minimizing drug irritation. J Pharm Pharmacol. 2019, 71:1209-21. 10.1111\/jphp.13106","journal-title":"J Pharm Pharmacol"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1080\/10837450.2016.1219916","article-title":"Mucoadhesive niosomal in situ gel for ocular tissue targeting: in vitro and in vivo evaluation of lomefloxacin hydrochloride","volume":"22","author":"Abdelbary A","year":"2017","unstructured":"Abdelbary A, Salem HF, Khallaf RA, Ali AM. Mucoadhesive niosomal in situ gel for ocular tissue targeting: in vitro and in vivo evaluation of lomefloxacin hydrochloride. Pharm Dev Technol. 2017, 22:409-17. 10.1080\/10837450.2016.1219916","journal-title":"Pharm Dev Technol"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.18869\/acadpub.pbr.3.1.22","article-title":"Exploring the potential of complex-vesicle based niosomal ocular system loaded with azithromycin: development of in situ gel and ex vivo characterization","volume":"3","author":"Akhtar N","year":"2017","unstructured":"Akhtar N, Kumar Singh R, Pathak K. Exploring the potential of complex-vesicle based niosomal ocular system loaded with azithromycin: development of in situ gel and ex vivo characterization. Pharm Biomed Res. 2017, 3:22-33. 10.18869\/acadpub.pbr.3.1.22","journal-title":"Pharm Biomed Res"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2017.03.005","article-title":"Formulation development and evaluation of Natamycin niosomal in-situ gel for ophthalmic drug delivery","volume":"39","author":"Paradkar MU","year":"2017","unstructured":"Paradkar MU, Parmar M. Formulation development and evaluation of Natamycin niosomal in-situ gel for ophthalmic drug delivery. J Drug Deliv Sci Technol. 2017, 39:113-22. 10.1016\/j.jddst.2017.03.005","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2019.06.022","article-title":"Design and in vitro evaluation of doxycycline hyclate niosomes as a potential ocular delivery system","volume":"567","author":"Gugleva V","year":"2019","unstructured":"Gugleva V, Titeva S, Rangelov S, Momekova D. Design and in vitro evaluation of doxycycline hyclate niosomes as a potential ocular delivery system. Int J Pharm. 2019, 567:118431. 10.1016\/j.ijpharm.2019.06.022","journal-title":"Int J Pharm"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-09195-9","article-title":"Effects of imipenem-containing niosome nanoparticles against high prevalence methicillin-resistant Staphylococcus epidermidis biofilm formed","volume":"12","author":"Piri-Gharaghie T","year":"2022","unstructured":"Piri-Gharaghie T, Jegargoshe-Shirin N, Saremi-Nouri S, et al.. Effects of imipenem-containing niosome nanoparticles against high prevalence methicillin-resistant Staphylococcus epidermidis biofilm formed. Sci Rep. 2022, 12:5140. 10.1038\/s41598-022-09195-9","journal-title":"Sci Rep"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-023-02812-1","article-title":"Surfactant nanovesicles for augmented antibacterial activity against carbapenemase resistant enterobacteriaceae and extended spectrum beta-lactamases producing bacteria: in vitro and in vivo evaluation","volume":"23","author":"Abo Kamer AM","year":"2023","unstructured":"Abo Kamer AM, Amer NM, Abdelmegeed AA, El Maghraby GM, Gamaleldin NM. Surfactant nanovesicles for augmented antibacterial activity against carbapenemase resistant enterobacteriaceae and extended spectrum beta-lactamases producing bacteria: in vitro and in vivo evaluation. BMC Microbiol. 2023, 23:73. 10.1186\/s12866-023-02812-1","journal-title":"BMC Microbiol"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2020.104231","article-title":"Preparation and optimization of ciprofloxacin encapsulated niosomes: a new approach for enhanced antibacterial activity, biofilm inhibition and reduced antibiotic resistance in ciprofloxacin-resistant methicillin-resistance Staphylococcus aureus","volume":"103","author":"Mirzaie A","year":"2020","unstructured":"Mirzaie A, Peirovi N, Akbarzadeh I, et al.. Preparation and optimization of ciprofloxacin encapsulated niosomes: a new approach for enhanced antibacterial activity, biofilm inhibition and reduced antibiotic resistance in ciprofloxacin-resistant methicillin-resistance Staphylococcus aureus. Bioorg Chem. 2020, 103:104231. 10.1016\/j.bioorg.2020.104231","journal-title":"Bioorg Chem"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8815969","article-title":"Efficacy of levofloxacin loaded nonionic surfactant vesicles (niosomes) in a model of Pseudomonas aeruginosa infected Sprague Dawley rats","volume":"2020","author":"Jankie S","year":"2020","unstructured":"Jankie S, Johnson J, Adebayo AS, Pillai GK, Pinto Pereira LM. Efficacy of levofloxacin loaded nonionic surfactant vesicles (niosomes) in a model of Pseudomonas aeruginosa infected Sprague Dawley rats. Adv Pharmacol Pharm Sci. 2020, 2020:8815969. 10.1155\/2020\/8815969","journal-title":"Adv Pharmacol Pharm Sci"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.9734\/BJPR\/2016\/30380","article-title":"Acute and subacute toxicity of sorbitan monostearate (Span 60) non-ionic surfactant vesicles (niosomes) in Sprague Dawley rats","volume":"14","author":"Jankie S","year":"2016","unstructured":"Jankie S, Johnson J, Adebayo AS, Pillai GK, Pinto Pereira LM. Acute and subacute toxicity of sorbitan monostearate (Span 60) non-ionic surfactant vesicles (niosomes) in Sprague Dawley rats. J Pharm Res Int. 2016, 14:1-9. 10.9734\/BJPR\/2016\/30380","journal-title":"J Pharm Res Int"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1088\/1748-605X\/abc7f2","article-title":"Effects of cefazolin-containing niosome nanoparticles against methicillin-resistant Staphylococcus aureus biofilm formed on chronic wounds","volume":"16","author":"Zafari M","year":"2021","unstructured":"Zafari M, Adibi M, Chiani M, et al.. Effects of cefazolin-containing niosome nanoparticles against methicillin-resistant Staphylococcus aureus biofilm formed on chronic wounds. Biomed Mater. 2021, 16:035001. 10.1088\/1748-605X\/abc7f2","journal-title":"Biomed Mater"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201807-1318OC","article-title":"Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT). A prospective, open-label, randomized study","volume":"198","author":"Griffith DE","year":"2018","unstructured":"Griffith DE, Eagle G, Thomson R, et al.. Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT). A prospective, open-label, randomized study. Am J Respir Crit Care Med. 2018, 198:1559-69. 10.1164\/rccm.201807-1318OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-022-01268-6","article-title":"A phase I first-in-man study to investigate the pharmacokinetics and safety of liposomal dexamethasone in patients with progressive multiple myeloma","volume":"13","author":"Metselaar J","year":"2023","unstructured":"Metselaar J, Lammers T, Boquoi A, et al.. A phase I first-in-man study to investigate the pharmacokinetics and safety of liposomal dexamethasone in patients with progressive multiple myeloma. Drug Deliv Transl Res. 2023, 13:915-23. 10.1007\/s13346-022-01268-6","journal-title":"Drug Deliv Transl Res"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-021-04371-6","article-title":"Phase I study of pegylated liposomal doxorubicin and cisplatin in patients with advanced osteosarcoma","volume":"89","author":"Wen XZ","year":"2022","unstructured":"Wen XZ, Pan QZ, Xu BS, et al.. Phase I study of pegylated liposomal doxorubicin and cisplatin in patients with advanced osteosarcoma. Cancer Chemother Pharmacol. 2022, 89:209-15. 10.1007\/s00280-021-04371-6","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2022-004028","article-title":"Clinical and molecular signature of survival and resistance to olaparib plus pegylated liposomal doxorubicin in platinum-resistant ovarian cancer: a stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601","volume":"33","author":"Perez-Fidalgo JA","year":"2023","unstructured":"Perez-Fidalgo JA, Guerra E, Garc\u00eda Y, et al.. Clinical and molecular signature of survival and resistance to olaparib plus pegylated liposomal doxorubicin in platinum-resistant ovarian cancer: a stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601. Int J Gynecol Cancer. 2023, 33:929-36. 10.1136\/ijgc-2022-004028","journal-title":"Int J Gynecol Cancer"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30332-2","article-title":"Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial","volume":"19","author":"Lyon PC","year":"2018","unstructured":"Lyon PC, Gray MD, Mannaris C, et al.. Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial. Lancet Oncol. 2018, 19:1027-39. 10.1016\/S1470-2045(18)30332-2","journal-title":"Lancet Oncol"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial","volume":"387","author":"Wang-Gillam A","year":"2016","unstructured":"Wang-Gillam A, Li CP, Bodoky G, et al.. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016, 387:545-57. 10.1016\/S0140-6736(15)00986-1","journal-title":"Lancet"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S146111","article-title":"The use of amikacin liposome inhalation suspension (Arikayce) in the treatment of refractory nontuberculous mycobacterial lung disease in adults","volume":"14","author":"Khan O","year":"2020","unstructured":"Khan O, Chaudary N. The use of amikacin liposome inhalation suspension (Arikayce) in the treatment of refractory nontuberculous mycobacterial lung disease in adults. Drug Des Devel Ther. 2020, 14:2287-94. 10.2147\/DDDT.S146111","journal-title":"Drug Des Devel Ther"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.2903\/j.efsa.2017.4788","article-title":"Re-evaluation of sorbitan monostearate (E\u00a0491), sorbitan tristearate (E\u00a0492), sorbitan monolaurate (E\u00a0493), sorbitan monooleate (E\u00a0494) and sorbitan monopalmitate (E\u00a0495) when used as food additives","volume":"15","author":"Mortensen A","year":"2017","unstructured":"Mortensen A, Aguilar F, Crebelli R, et al.. Re-evaluation of sorbitan monostearate (E\u00a0491), sorbitan tristearate (E\u00a0492), sorbitan monolaurate (E\u00a0493), sorbitan monooleate (E\u00a0494) and sorbitan monopalmitate (E\u00a0495) when used as food additives. EFSA J. 2017, 15:e04788. 10.2903\/j.efsa.2017.4788","journal-title":"EFSA J"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2019.11.017","article-title":"Development of novel nanoantibiotics using an outer membrane vesicle-based drug efflux mechanism","volume":"317","author":"Huang W","year":"2020","unstructured":"Huang W, Zhang Q, Li W, et al.. Development of novel nanoantibiotics using an outer membrane vesicle-based drug efflux mechanism. J Control Release. 2020, 317:1-22. 10.1016\/j.jconrel.2019.11.017","journal-title":"J Control Release"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/427007-nanovesicular-drug-delivery-systems-for-overcoming-antibiotic-resistance","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T01:42:39Z","timestamp":1765417359000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/427007-nanovesicular-drug-delivery-systems-for-overcoming-antibiotic-resistance"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":108,"URL":"https:\/\/doi.org\/10.7759\/cureus.98926","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,10]]}}}